Search

Your search keyword '"Santini D."' showing total 2,987 results

Search Constraints

Start Over You searched for: Author "Santini D." Remove constraint Author: "Santini D."
2,987 results on '"Santini D."'

Search Results

51. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline

52. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

54. 1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

55. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies

57. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

61. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

62. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

64. O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials

65. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes

66. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

67. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

68. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

69. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

70. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

74. P301 Non-familial small bowel carcinomas in Crohnʼs disease: clinico-pathological, molecular and prognostic features

78. First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

80. First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

85. Employment from Solar Energy: A Bright but Partly Cloudy Future.

86. Haploops similis Stephensen 1925

87. Haploops vallifera Stephensen 1925

88. Complement to the knowledge of the Haploops species (Crustacea, Gammaridea, Ampeliscidae), with the description of two new species from North Atlantic Ocean. [Contribution to the knowledge of the Haploops genus. 10.]

89. Haploops truncata Kaim-Malka & Bellan-Santini & Dauvin 2021, spec. nov

90. Haploops Liljeborg 1856

91. Haploops faroensis Kaim-Malka & Bellan-Santini & Dauvin 2021, spec. nov

92. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

93. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

96. 966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy

Catalog

Books, media, physical & digital resources